Moderna

MRNA is the ticker symbol for Moderna, a company classified under the Biotechnology industry within the broader Health Care sector.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Key metrics include a return on equity of -18.1%, a debt-to-equity ratio of 0.55.

The company reports trailing twelve-month revenue of $344.00M and net loss of $1.34B.

FINOTAUR aggregates real-time and fundamental data on MRNA to help traders and investors make informed decisions. Track MRNA in your trading journal alongside other positions for a unified view of your portfolio.